These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 26048147)
1. HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease. Li J; Heinrichs J; Haarberg K; Semple K; Veerapathran A; Liu C; Anasetti C; Yu XZ J Immunol; 2015 Jul; 195(2):717-25. PubMed ID: 26048147 [TBL] [Abstract][Full Text] [Related]
2. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice. Semple K; Yu Y; Wang D; Anasetti C; Yu XZ Biol Blood Marrow Transplant; 2011 Mar; 17(3):309-18. PubMed ID: 21224010 [TBL] [Abstract][Full Text] [Related]
3. Interleukin-27 Enforces Regulatory T Cell Functions to Prevent Graft-versus-Host Disease. Le HT; Keslar K; Nguyen QT; Blazar BR; Hamilton BK; Min B Front Immunol; 2020; 11():181. PubMed ID: 32117306 [TBL] [Abstract][Full Text] [Related]
4. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD. Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018 [TBL] [Abstract][Full Text] [Related]
5. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. Zhang P; Tey SK; Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Raju J; Leveque L; Markey KA; Varelias A; Clouston AD; Lane SW; MacDonald KP; Hill GR J Immunol; 2013 Nov; 191(10):5291-303. PubMed ID: 24123683 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic expansion of donor-derived, naturally occurring CD4(+)Foxp3(+) regulatory T cells reduces acute graft-versus-host disease lethality without abrogating the graft-versus-leukemia effect in murine models. Duramad O; Laysang A; Li J; Ishii Y; Namikawa R Biol Blood Marrow Transplant; 2011 Aug; 17(8):1154-68. PubMed ID: 21145405 [TBL] [Abstract][Full Text] [Related]
7. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210 [TBL] [Abstract][Full Text] [Related]
8. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease. Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967 [TBL] [Abstract][Full Text] [Related]
9. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Jones SC; Murphy GF; Korngold R Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217 [TBL] [Abstract][Full Text] [Related]
10. Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantation. Cao J; Chen C; Zeng L; Li L; Li Z; Xu K Leuk Res; 2010 Oct; 34(10):1374-82. PubMed ID: 20018376 [TBL] [Abstract][Full Text] [Related]
12. [Influence of donor Treg cells on GVHD and GVL effects after allogeneic bone marrow transplantation in mice]. Cao J; Chen C; Zeng LY; Li ZY; Cheng H; Pan XY; Xu KL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):181-4. PubMed ID: 20137143 [TBL] [Abstract][Full Text] [Related]
13. Isolation of human CD4/CD8 double-positive, graft-versus-host disease-protective, minor histocompatibility antigen-specific regulatory T cells and of a novel HLA-DR7-restricted HY-specific CD4 clone. Eljaafari A; Yuruker O; Ferrand C; Farre A; Addey C; Tartelin ML; Thomas X; Tiberghien P; Simpson E; Rigal D; Scott D J Immunol; 2013 Jan; 190(1):184-94. PubMed ID: 23225889 [TBL] [Abstract][Full Text] [Related]
14. Recipient type-specific engineered regulatory T cells prevent graft-vs-host disease after allogeneic bone marrow transplantation in mice. Chen C; Cao J; Zeng L; Li Y; Wang D; Xu K Transplant Proc; 2011 Jun; 43(5):2041-8. PubMed ID: 21693322 [TBL] [Abstract][Full Text] [Related]
15. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Johnson BD; Becker EE; Truitt RL Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958 [TBL] [Abstract][Full Text] [Related]
16. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice. Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029 [TBL] [Abstract][Full Text] [Related]
17. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Xia G; Truitt RL; Johnson BD Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723 [TBL] [Abstract][Full Text] [Related]
18. [Influence of mouse genetic engineering regulatory T cells infusion on post-allogeneic bone marrow transplantation acute graft-versus-host disease in mice]. Cao J; Li L; Chen C; Zeng LY; Li ZY; Pan XY; Xu KL Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):83-8. PubMed ID: 21429372 [TBL] [Abstract][Full Text] [Related]
19. Generation of allo-antigen-specific induced Treg stabilized by vitamin C treatment and its application for prevention of acute graft versus host disease model. Kasahara H; Kondo T; Nakatsukasa H; Chikuma S; Ito M; Ando M; Kurebayashi Y; Sekiya T; Yamada T; Okamoto S; Yoshimura A Int Immunol; 2017 Dec; 29(10):457-469. PubMed ID: 29126272 [TBL] [Abstract][Full Text] [Related]
20. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. Sykes M; Abraham VS; Harty MW; Pearson DA J Immunol; 1993 Jan; 150(1):197-205. PubMed ID: 8093257 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]